drugset / Trial / NCT00090259

Study to Evaluate Potential Decrease in Hospitalization Events, Time Between Events, and Increasing Longevity in Patients With Symptomatic Heart Failure (0954-948)

NCT00090259

Phase 3 Completed 3834 enrolled Organon and Co
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a multicenter study to evaluate potential decrease in hospitalization events and time between events and increasing longevity in patients with symptomatic congestive heart failure and intolerant of first-line medication for heart failure. This study will evaluate if higher doses of the investigational drug given daily will be superior to the lower dose of the same investigational drug given daily.

Timeline

Start
2001-12-19
Primary completion
2009-03-31
Completion
2009-05-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Losartan Other / unclassified 50 mg Oral
Subject Losartan Other / unclassified 150 mg Oral

Indications